<DOC>
	<DOCNO>NCT01194284</DOCNO>
	<brief_summary>This study observational safety surveillance study design prospectively assess patient high-grade osteosarcoma candidate treatment mifamurtide within context prevail standard oncology practice</brief_summary>
	<brief_title>Surveillance Study Patients With Newly Diagnosed Osteosarcoma</brief_title>
	<detailed_description />
	<mesh_term>Osteosarcoma</mesh_term>
	<mesh_term>Mifamurtide</mesh_term>
	<criteria>Inclusion Criteria Each patient must meet follow inclusion criterion enrol study : Male female age 2 40 year Confirmed pathological diagnosis newlydiagnosed , nonmetastatic , resectable , primary , highgrade osteosarcoma Have complete definitive surgery ( local ablation technique ) Have treatment regimen include mifamurtide minimum 2 recognize chemotherapy agent treatment osteosarcoma ( cisplatin , doxorubicin , highdose methotrexate ifosfamide ) Organ function deem satisfactory receive plan chemotherapy contain minimum 2 recognize chemotherapy agent treatment osteosarcoma Voluntary Written Consent Exclusion Criteria Patients meeting follow exclusion criterion enrol study : Female patient lactate breastfeed positive serum pregnancy test screen period History pericarditis pleuritis Have lowgrade osteosarcoma parosteal periosteal sarcoma Have osteosarcoma associate Paget 's disease Current treatment anticancer investigational product time enrollment study</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>